Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID S CHIN YEE

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1740424563
CMS profile
34172
Location
ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$176,403.10

200 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID S CHIN YEE

NPI 1740424563 · CMS profile ID 34172

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740424563?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID S CHIN YEE, NPI 1740424563, CMS profile ID 34172. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740424563?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DAVID S CHIN YEE, NPI 1740424563, CMS profile ID 34172. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740424563?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DAVID S CHIN YEE, NPI 1740424563, CMS profile ID 34172, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1740424563?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

200 matching records · $176,403.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 200 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 200.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Apellis Pharmaceuticals, Inc. $26.1406/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056308437 CMS
Apellis Pharmaceuticals, Inc. $16.0006/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056333869 CMS
Apellis Pharmaceuticals, Inc. $47.3806/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056377655 CMS
Alimera Sciences, Inc. $33.3305/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993543047 CMS
Genentech USA, Inc. $9.9805/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345181 CMS
Apellis Pharmaceuticals, Inc. $6,246.0005/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056363613 CMS
Alimera Sciences, Inc. $20.5205/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993542889 CMS
Apellis Pharmaceuticals, Inc. $237.4805/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056329549 CMS
Apellis Pharmaceuticals, Inc. $447.8005/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056332568 CMS
Apellis Pharmaceuticals, Inc. $121.1705/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056376455 CMS
AbbVie Inc. $16.9705/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996425145 CMS
Regeneron Pharmaceuticals, Inc. $143.0605/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000003233 CMS
Genentech USA, Inc. $2,120.0005/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345307 CMS
Apellis Pharmaceuticals, Inc. $4,914.0005/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056339849 CMS
Genentech USA, Inc. $24.9605/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345207 CMS
Apellis Pharmaceuticals, Inc. $125.0005/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056358649 CMS
Regeneron Healthcare Solutions, Inc. $20.7404/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999123283 CMS
Regeneron Healthcare Solutions, Inc. $25.4504/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999123279 CMS
Apellis Pharmaceuticals, Inc. $32.7304/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056347247 CMS
EyePoint Pharmaceuticals US, Inc. $28.9004/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017487163 CMS
Genentech USA, Inc. $63.4204/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345353 CMS
Genentech USA, Inc. $22.4604/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345217 CMS
Regeneron Healthcare Solutions, Inc. $1,848.0004/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999123275 CMS
Apellis Pharmaceuticals, Inc. $123.6504/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056305693 CMS
Apellis Pharmaceuticals, Inc. $1,500.0003/29/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056319785 CMS
Regeneron Healthcare Solutions, Inc. $34.3203/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999123271 CMS
Apellis Pharmaceuticals, Inc. $25.2303/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056319775 CMS
Genentech USA, Inc. $23.2703/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345203 CMS
Coherus Biosciences Inc. $17.5203/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060238551 CMS
AbbVie Inc. $16.3002/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996425141 CMS
Genentech USA, Inc. $414.8202/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345365 CMS
Genentech USA, Inc. $414.8202/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061207928 CMS
Genentech USA, Inc. $331.8502/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061207930 CMS
Genentech USA, Inc. $43.4002/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061207932 CMS
Genentech USA, Inc. $5,300.0002/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061207934 CMS
Genentech USA, Inc. $28.0002/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061207936 CMS
Genentech USA, Inc. $79.9502/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345229 CMS
Apellis Pharmaceuticals, Inc. $2,268.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056333887 CMS
Genentech USA, Inc. $24.9602/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345169 CMS
Genentech USA, Inc. $19.9002/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345361 CMS
AbbVie Inc. $84.8402/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996425139 CMS
EyePoint Pharmaceuticals US, Inc. $20.0802/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017489665 CMS
Alimera Sciences, Inc. $16.7202/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993541329 CMS
Regeneron Healthcare Solutions, Inc. $29.0001/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999123267 CMS
Sight Sciences, Inc. $146.5901/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056679877 CMS
Genentech USA, Inc. $7.4701/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345177 CMS
Apellis Pharmaceuticals, Inc. $1,500.0001/19/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056314195 CMS
Apellis Pharmaceuticals, Inc. $21.9901/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056352241 CMS
Alimera Sciences, Inc. $68.5701/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993541083 CMS
AbbVie Inc. $16.7001/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996425135 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $42,611.21 77
PY2020 $17,690.30 42
PY2021 $35,552.53 77
PY2022 $73,412.66 142
PY2023 $176,403.10 200
PY2024 $271,580.02 286
PY2025 $198,843.89 220

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $98,971.36 68

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 12/23/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279708
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,647.08 12/19/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,617.42 12/19/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278050
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,591.22 12/19/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278052
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,062.00 12/15/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,793.00 12/15/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,577.52 12/11/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,764.35 11/19/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184261885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,764.35 11/19/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184261887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,764.35 10/29/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,764.35 10/29/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254339
Principal investigator 1 Notal Vision, Inc. $30.00 10/14/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740642
Principal investigator 1 Notal Vision, Inc. $60.00 10/14/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740644
Principal investigator 1 Notal Vision, Inc. $30.00 10/14/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740646
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,391.94 10/03/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,391.94 10/03/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,764.35 10/03/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,391.94 10/03/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,764.35 10/03/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 09/17/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184237762
Principal investigator 1 Notal Vision, Inc. $30.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740624
Principal investigator 1 Notal Vision, Inc. $60.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740626
Principal investigator 1 Notal Vision, Inc. $30.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740630
Principal investigator 1 Notal Vision, Inc. $30.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740632
Principal investigator 1 Notal Vision, Inc. $30.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740634
Principal investigator 1 Notal Vision, Inc. $60.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740636
Principal investigator 1 Notal Vision, Inc. $30.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740638
Principal investigator 1 Notal Vision, Inc. $30.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740640
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 07/18/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184217374
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,365.74 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215082
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215084
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,365.74 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215086
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215090
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.00 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,793.00 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 06/02/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 06/02/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 04/23/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 04/23/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186229
Principal investigator 1 Notal Vision, Inc. $60.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740598
Principal investigator 1 Notal Vision, Inc. $60.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740600
Principal investigator 1 Notal Vision, Inc. $60.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740602
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740604
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740608
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740610
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740612
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740614
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740616
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740618
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740620
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740622
Principal investigator 1 Notal Vision, Inc. $60.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740580
Principal investigator 1 Notal Vision, Inc. $60.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740582
Principal investigator 1 Notal Vision, Inc. $30.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740586
Principal investigator 1 Notal Vision, Inc. $30.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740588
Principal investigator 1 Notal Vision, Inc. $30.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740590
Principal investigator 1 Notal Vision, Inc. $30.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740592
Principal investigator 1 Notal Vision, Inc. $30.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740594
Principal investigator 1 Notal Vision, Inc. $30.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740596
Principal investigator 1 Notal Vision, Inc. $60.00 04/15/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740570
Principal investigator 1 Notal Vision, Inc. $30.00 04/15/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740572
Principal investigator 1 Notal Vision, Inc. $30.00 04/15/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740574
Principal investigator 1 Notal Vision, Inc. $30.00 04/15/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740576
Principal investigator 1 Notal Vision, Inc. $30.00 04/15/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740578
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,963.72 03/12/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171074
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,963.72 03/12/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171076